ApoGen Biotechnologies

company

About

ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$7M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2014
Number Of Employee
1 - 10
Operating Status
Active

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$7M
ApoGen Biotechnologies has raised a total of $7M in funding over 2 rounds. Their latest funding was raised on Dec 12, 2016 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 12, 2016 Series A $7M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
ApoGen Biotechnologies is funded by 2 investors. ARCH Venture Partners and Watson Fund are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series A
Watson Fund Series A